BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37037826)

  • 21. Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms.
    Grabuschnig S; Bronkhorst AJ; Holdenrieder S; Rosales Rodriguez I; Schliep KP; Schwendenwein D; Ungerer V; Sensen CW
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33137955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq).
    Liu X; Ren J; Luo N; Guo H; Zheng Y; Li J; Tang F; Wen L; Peng J
    Clin Epigenetics; 2019 Jun; 11(1):93. PubMed ID: 31234922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
    Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
    Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
    Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
    Luo H; Wei W; Ye Z; Zheng J; Xu RH
    Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
    Woodhouse R; Li M; Hughes J; Delfosse D; Skoletsky J; Ma P; Meng W; Dewal N; Milbury C; Clark T; Donahue A; Stover D; Kennedy M; Dacpano-Komansky J; Burns C; Vietz C; Alexander B; Hegde P; Dennis L
    PLoS One; 2020; 15(9):e0237802. PubMed ID: 32976510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
    Razavi P; Li BT; Brown DN; Jung B; Hubbell E; Shen R; Abida W; Juluru K; De Bruijn I; Hou C; Venn O; Lim R; Anand A; Maddala T; Gnerre S; Vijaya Satya R; Liu Q; Shen L; Eattock N; Yue J; Blocker AW; Lee M; Sehnert A; Xu H; Hall MP; Santiago-Zayas A; Novotny WF; Isbell JM; Rusch VW; Plitas G; Heerdt AS; Ladanyi M; Hyman DM; Jones DR; Morrow M; Riely GJ; Scher HI; Rudin CM; Robson ME; Diaz LA; Solit DB; Aravanis AM; Reis-Filho JS
    Nat Med; 2019 Dec; 25(12):1928-1937. PubMed ID: 31768066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer.
    Shinjo K; Hara K; Nagae G; Umeda T; Katsushima K; Suzuki M; Murofushi Y; Umezu Y; Takeuchi I; Takahashi S; Okuno Y; Matsuo K; Ito H; Tajima S; Aburatani H; Yamao K; Kondo Y
    PLoS One; 2020; 15(6):e0233782. PubMed ID: 32520974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
    Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
    EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets.
    Che H; Jatsenko T; Lenaerts L; Dehaspe L; Vancoillie L; Brison N; Parijs I; Van Den Bogaert K; Fischerova D; Heremans R; Landolfo C; Testa AC; Vanderstichele A; Liekens L; Pomella V; Wozniak A; Dooms C; Wauters E; Hatse S; Punie K; Neven P; Wildiers H; Tejpar S; Lambrechts D; Coosemans A; Timmerman D; Vandenberghe P; Amant F; Vermeesch JR
    Clin Chem; 2022 Sep; 68(9):1164-1176. PubMed ID: 35769009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.
    Liu MC; Oxnard GR; Klein EA; Swanton C; Seiden MV;
    Ann Oncol; 2020 Jun; 31(6):745-759. PubMed ID: 33506766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying the tissues-of-origin of circulating cell-free DNAs is a promising way in noninvasive diagnostics.
    Peng X; Li HD; Wu FX; Wang J
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32427285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
    Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
    Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.
    Li S; Zeng W; Ni X; Zhou Y; Stackpole ML; Noor ZS; Yuan Z; Neal A; Memarzadeh S; Garon EB; Dubinett SM; Li W; Zhou XJ
    Clin Cancer Res; 2022 May; 28(9):1841-1853. PubMed ID: 35149536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
    Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
    Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer.
    Tian J; Geng Y; Lv D; Li P; Cordova M; Liao Y; Tian X; Zhang X; Zhang Q; Zou K; Zhang Y; Zhang X; Li Y; Zhang J; Ma Z; Shao Y; Song L; Owen GI; Li T; Liu R; Liu Q; Zou L; Zhang Z; Li Z
    Int J Cancer; 2019 Nov; 145(9):2547-2557. PubMed ID: 30919951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma DNA for early cancer detection - opportunities and challenges.
    Lam WKJ; Chan KCA
    Expert Rev Mol Diagn; 2019 Jan; 19(1):5-7. PubMed ID: 30513010
    [No Abstract]   [Full Text] [Related]  

  • 40. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
    Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
    Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.